4H5T image
Entry Detail
PDB ID:
4H5T
Keywords:
Title:
HSC70 NBD with ADP and Mg
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2012-09-18
Release Date:
2014-03-19
Method Details:
Experimental Method:
Resolution:
1.90 Å
R-Value Free:
0.29
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Heat shock cognate 71 kDa protein
Chain IDs:A
Chain Length:383
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
New crystal structures of HSC-70 ATP binding domain confirm the role of individual binding pockets and suggest a new method of inhibition.
Biochimie 108 186 192 (2015)
PMID: 25433210 DOI: 10.1016/j.biochi.2014.11.012

Abstact

In recent years the chaperone HSC-70 has become a target for drug design with a strong focus in anticancer therapies. In our study of possible inhibitors of HSC-70 enzymatic activity we screened compounds by NMR as well as X-ray crystallography. As part of our screening efforts we crystallized the human HSC-70 ATP binding domain and obtained novel crystal forms in addition to known structures. The new crystal structures highlight the mobility of the entire domain previously described by NMR, which was linked to its chaperone activity but not yet demonstrated by X-ray crystallography. Conformational changes across the entire molecule have been elucidated in response to the binding of small molecule ligands and show a pattern of mobility consistent with postulated signal transduction modes between the nucleotide binding domain (NBD) and the substrate binding domain (SBD). In addition, two crystal structures contained glycerol bound at a new site. Binding studies performed with glycerol analogs proved inhibitory properties of the site, which were further characterized by isothermal calorimetry and in silico docking studies. The presence of two binding pockets enabled us to explore a novel method of inhibition by compounds that bridge the adjacent phosphate and glycerol binding sites. Finally, an example of such a bridged inhibitor is proposed.

Legend

Protein

Chemical

Disease

Primary Citation of related structures